ClinicalTrials.gg
CompletedNCT02464969Updated Oct 29, 2024Results posted

Apixaban for the Acute Treatment of Venous Thromboembolism in Children

A Phase 4 interventional study of Apixaban and Standard of Care in Venous Thromboembolism, sponsored by Bristol-Myers Squibb. Completed at 128 sites in 13 countries. Open to participants aged 0 Days to 17 Years. Per ClinicalTrials.gov, last updated 2024-10-29.

Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
229
Allocation
Randomized
Ages
0 Days to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 37 studies testing apixaban in Venous Thromboembolism — 11 open to participants now, 11 under way, 1 of them phase 3. apixaban · Venous Thromboembolism.

Enrollment
15th of 37
229 · median 100
Started
2015
with 2 others
Phase 4
14 of 37
5 open now
Registered
5th of 37
by date
Lead sponsor
3 of 37
Bristol-Myers Squibb

Among the 37 studies testing apixaban in Venous Thromboembolism, this one is the 15th largest by enrollment, is one of 3 that started in 2015, is one of 14 in phase 4, and was the 5th registered.

Venous Thromboembolism

713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

11 of the 37 studies testing apixaban in Venous Thromboembolism are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About apixaban

apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 0 Days to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing apixaban in Venous Thromboembolism, or all of them as a file.
02

Study summary

To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.

03

Conditions studied

  • Venous Thromboembolism

Keywords

  • VTE, thromboembolism, thrombosis, embolism, apixaban, Eliquis
04

Who can participate

Ages eligible
0 Days to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Birth to \<18 years of age with a minimum weight of 2.6 kg at the time of randomization.
  2. Presence of an index VTE which is confirmed by imaging.
  3. Intention to manage the index VTE with anticoagulation treatment for at least 6 to 12 weeks.
  4. Subjects able to tolerate oral feeding, nasogastric (NG), gastric (G) feeding and are currently tolerating enteric medications, as per investigator's judgement.

Exclusion criteria

Exclusion Criteria:

  1. Anticoagulant treatment for the index VTE for greater than 14 days prior to randomization. Neonates that are enrolled into the PK cohort must be on a minimum of 5 days and a maximum of 14 days SOC anticoagulation prior to randomization. Neonates that are enrolled into the post PK cohort may receive SOC anticoagulation for up to 14 days prior to randomization.
  2. Thrombectomy, thrombolytic therapy, or insertion of a caval filter to treat the index VTE.
  3. A mechanical heart valve.
  4. Active bleeding or high risk of bleeding at the time of randomization.
  5. Intracranial bleed, including intraventricular hemorrhage, within 3 months prior to randomization.
  6. Abnormal baseline liver function at randomization.
  7. Inadequate renal function at the time of randomization.
  8. count \<50×109 per L at randomization.
  9. Uncontrolled severe hypertension at the time of randomization.
  10. Use of prohibited concomitant medication at the time of randomization.
  11. Female subjects who are either pregnant or breastfeeding a child.
  12. Use of aggressive life-saving therapies such as ventricular assist devices (VAD) or extracorporeal membrane oxygenation (ECMO) at the time of enrollment.
  13. Unable to take oral or enteric medication via the NG or G tube.
  14. Known inherited or acquired antiphospholipid syndrome (APS).
  15. Known inherited bleeding disorder or coagulopathy with increased bleeding risk (eg, hemophilia, von Willebrand disease, etc.)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
229 participants (actual)

Study arms

  • Experimental
    Apixaban

    Subjects between birth to \<18 years will be dosed on a body weight tiered regimen. Subjects ≥35kg will receive 10mg twice daily(BID) for 7 days followed by 5mg BID thereafter;\<35kg to 25kg will receive 8mg BID for 7 days followed by 4mg BID thereafter;\<25 to 18kg will receive 6mg BID for 7 days and then 3mg BID thereafter;\<18 to 12kg will receive 4mg BID for 7 days and then 2mg BID thereafter;\<12 to 9kg will receive 3mg BID for 7 days and then 1.5mg BID thereafter;\< 9kg to 6kg will receive 2 mg BID for 7 days and 1mg BID thereafter;\<6kg to 5kg will receive 1mg BID for 7 days and 0.5mg BID thereafter;\<5kg to 4kg will receive 0.6mg twice daily for 7 days and 0.3mg BID thereafter;PK cohort neonates ≥ 2.6kg will receive 0.1mg BID. Dose will be adjusted as determined by PK measurements (ie, to 0.2mg BID, 0.1mg daily or dose will stay the same).For the post PK cohort Neonates ˂4kg to 2.6kg, if confirmed by PK sub analysis,subjects will receive 0.2mg BID for 7 days and 0.1mg BID thereafter.

    Drug: Apixaban · Drug: Standard of Care

Interventions

  • Tablet or Solution

  • DrugStandard of Care

    Unfractionated heparin, low molecular weight heparin, and/or a vitamin K antagonist. For subjects under 2 years of age, standard of care will be limited to unfractionated heparin or low molecular weight heparin.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Composite of Major and Clinically Relevant Non-Major (CRNM) Bleeding

    Bleeding definitions are based on the Perinatal and Paediatric Haemostasis Subcommittee of the International Society on Thrombosis and Haemostasis (ISTH) criteria. Major bleeding includes: (i) fatal bleeding; (ii) clinically overt bleeding with a decrease in Hgb of at least 20 g/L (2 g/dL) in 24 hours; (iii) retroperitoneal, pulmonary, intracranial, or central nervous system bleeding; and (iv) bleeding requiring surgical intervention in an operating suite (including interventional radiology). Clinically relevant non-major bleeding includes: (i) overt bleeding requiring a blood product not attributable to the participant's underlying condition; and (ii) bleeding requiring medical or surgical intervention to restore hemostasis, other than in an operating suite.

    Time frame: From first dose (Day 1) up to 114 days

  2. Percentage of Participants With Symptomatic and Asymptomatic Recurrent Venous Thromboembolism (VTE) and VTE-Related Mortality

    Recurrent VTE, defined as either contiguous progression or non-contiguous new thrombus and including, but not limited to deep vein thrombosis (DVT), pulmonary embolism (PE) and paradoxical embolism. 95% CI was from the Agresti-Coull method.

    Time frame: From first dose (Day 1) up to 114 days

Secondary outcomes

  1. Percentage of Participants Who Died

    Death due to any cause was assessed. 95% CI was calculated using the Agresti-Coull method.

    Time frame: From first dose (Day 1) up to 114 days

  2. Percentage of Participants With Venous Thromboembolism (VTE)-Related Mortality

    Participants were assessed for death due to Venous Thromboembolism (VTE).

    Time frame: From first dose (Day 1) up to 114 days

  3. Number of Participants With Index Venous Thromboembolism (VTE) Status

    Index VTE status was defined as the last image obtained during the Main treatment phase for each participant's comparison to baseline imaging. Index VTE status was classified as Recurrence-contiguous; Recurrence-new; Unchanged; Regression; Resolution; Indeterminate/Nondiagnostic. Participants could have multiple concomitant index events. Regression was defined as (ie, unequivocal decrease \[\>50%\] of the total volume/mass of the thrombus compared to the index event)

    Time frame: From first dose (Day 1) up to 91 days

  4. Percentage of Participants With Stroke

    Participants were assessed for incidence of stroke.

    Time frame: From first dose (Day 1) up to 114 days

  5. Percentage of Participants With Symptomatic and Asymptomatic Recurrent Venous Thromboembolism (VTE)

    Recurrent VTE, defined as either contiguous progression or non-contiguous new thrombus and including, but not limited to deep vein thrombosis (DVT), pulmonary embolism (PE) and paradoxical embolism. 95% CI was from the Agresti-Coull method.

    Time frame: From first dose (Day 1) up to 114 days

  6. Number of Participants With New Symptomatic or Asymptomatic Deep Vein Thrombosis (DVT) and New Symptomatic or Asymptomatic Pulmonary Embolism (PE)

    Participants were assessed for incidence of Symptomatic or Asymptomatic Deep Vein Thrombosis (DVT) and New Symptomatic or Asymptomatic Pulmonary Embolism (PE).

    Time frame: From first dose (Day 1) up to 114 days

  7. Percentage of Participants With Other Symptomatic and Asymptomatic Venous Thromboembolism (VTE)

    Other VTE included events such as cerebral sinovenous thrombosis, renal vein thrombosis, portal vein thrombosis, catheter-related VTE, and splanchnic thrombosis. If VTE event type was blank, it was included in the Other VTE. 95% CI was from the Agresti-Coull method.

    Time frame: From first dose (Day 1) up to 114 days

  8. Number of Participants With Clinically Relevant Non-Major (CRNM) Bleeding, Major Bleeding and Minor Bleeding

    Bleeding definitions are based on the Perinatal and Paediatric Haemostasis Subcommittee of the International Society on Thrombosis and Haemostasis (ISTH) criteria. Major bleeding includes: (i) fatal bleeding; (ii) clinically overt bleeding with a decrease in Hgb of at least 20 g/L (2 g/dL) in 24 hours; (iii) retroperitoneal, pulmonary, intracranial, or central nervous system bleeding; and (iv) bleeding requiring surgical intervention in an operating suite (including interventional radiology). Clinically relevant non-major bleeding includes: (i) overt bleeding requiring a blood product not attributable to the participant's underlying condition; and (ii) bleeding requiring medical or surgical intervention to restore hemostasis, other than in an operating suite. Minor bleeding was defined as any overt or macroscopic evidence of bleeding that does not fulfill the above criteria for either major bleeding or clinically relevant, non-major bleeding.

    Time frame: From first dose (Day 1) up to 114 days

  9. Blood Concentration of Apixaban (ng/mL)

    Blood samples were collected to assess the apixaban concentration at specified timepoints. Day 1 PK concentrations were only collected for participants in the Birth to ≤27 days arm. The lower limit of quantification (LLOQ) is 1.0 ng/mL for plasma samples, and 0.5 ng/mL for dried blood samples.

    Time frame: 3 hour (H), 12 H, 24 H at Day 3; pre and post dose at Day 14 and Day 42

  10. Concentration of Plasma Anti-Factor Xa (ng/mL)

    Blood samples were collected to assess the Anti-Factor Xa concentration at specified timepoints. Day 1 PK concentrations were only collected for participants in the Birth to ≤27 days arm. The lower limit of quantification (LLOQ) is 35.0 ng/mL.

    Time frame: Pre and post dose at Day 14 and Day 42

07

Results

Posted Oct 29, 2024

Participant flow

Main Phase (Day 1 to Day 84)
Participant flow — Main Phase (Day 1 to Day 84)
MilestoneParticipants Receiving ApixabanParticipants Treated With Standard of Care
Started15574
Completed13865
Not completed179
Withdrew: Adverse event70
Withdrew: Death11
Withdrew: Lost to follow-up30
Withdrew: Withdrawal by parent/guardian04
Withdrew: No longer meets eligibility criteria01
Withdrew: Other reasons42
Withdrew: Entrance criteria11
Withdrew: Withdrawal by subject10
Extension Phase (Day 85 to Day 168)
Participant flow — Extension Phase (Day 85 to Day 168)
MilestoneParticipants Receiving ApixabanParticipants Treated With Standard of Care
Started530
Completed500
Not completed30
Withdrew: Adverse event10
Withdrew: Withdrawal by parent/guardian10
Withdrew: Other reasons10

Outcome measures

PrimaryPercentage of Participants With Composite of Major and Clinically Relevant Non-Major (CRNM) Bleeding

Bleeding definitions are based on the Perinatal and Paediatric Haemostasis Subcommittee of the International Society on Thrombosis and Haemostasis (ISTH) criteria. Major bleeding includes: (i) fatal bleeding; (ii) clinically overt bleeding with a decrease in Hgb of at least 20 g/L (2 g/dL) in 24 hours; (iii) retroperitoneal, pulmonary, intracranial, or central nervous system bleeding; and (iv) bleeding requiring surgical intervention in an operating suite (including interventional radiology). Clinically relevant non-major bleeding includes: (i) overt bleeding requiring a blood product not attributable to the participant's underlying condition; and (ii) bleeding requiring medical or surgical intervention to restore hemostasis, other than in an operating suite.

Time frame:
From first dose (Day 1) up to 114 days
Reported as:
Number · percentage of participants
Percentage of Participants With Composite of Major and Clinically Relevant Non-Major (CRNM) Bleeding
percentage of participantsParticipants Receiving ApixabanParticipants Treated With Standard of Care
Percentage of Participants With Composite of Major and Clinically Relevant Non-Major (CRNM) Bleeding1.3 (0.1 to 5.0)1.4 (0.0 to 8.1)
PrimaryPercentage of Participants With Symptomatic and Asymptomatic Recurrent Venous Thromboembolism (VTE) and VTE-Related Mortality

Recurrent VTE, defined as either contiguous progression or non-contiguous new thrombus and including, but not limited to deep vein thrombosis (DVT), pulmonary embolism (PE) and paradoxical embolism. 95% CI was from the Agresti-Coull method.

Time frame:
From first dose (Day 1) up to 114 days
Reported as:
Number · percentage of participants
Percentage of Participants With Symptomatic and Asymptomatic Recurrent Venous Thromboembolism (VTE) and VTE-Related Mortality
percentage of participantsParticipants Receiving ApixabanParticipants Treated With Standard of Care
Percentage of Participants With Symptomatic and Asymptomatic Recurrent Venous Thromboembolism (VTE) and VTE-Related Mortality2.6 (0.8 to 6.7)2.7 (0.2 to 9.9)
SecondaryPercentage of Participants Who Died

Death due to any cause was assessed. 95% CI was calculated using the Agresti-Coull method.

Time frame:
From first dose (Day 1) up to 114 days
Reported as:
Number · percentage of participants
Percentage of Participants Who Died
percentage of participantsParticipants Receiving ApixabanParticipants Treated With Standard of Care
Percentage of Participants Who Died1.3 (0.1 to 4.9)1.4 (0.0 to 8.0)
SecondaryPercentage of Participants With Venous Thromboembolism (VTE)-Related Mortality

Participants were assessed for death due to Venous Thromboembolism (VTE).

Time frame:
From first dose (Day 1) up to 114 days
Reported as:
Number · percentage of participants
Percentage of Participants With Venous Thromboembolism (VTE)-Related Mortality
percentage of participantsParticipants Receiving ApixabanParticipants Treated With Standard of Care
Percentage of Participants With Venous Thromboembolism (VTE)-Related Mortality00
SecondaryNumber of Participants With Index Venous Thromboembolism (VTE) Status

Index VTE status was defined as the last image obtained during the Main treatment phase for each participant's comparison to baseline imaging. Index VTE status was classified as Recurrence-contiguous; Recurrence-new; Unchanged; Regression; Resolution; Indeterminate/Nondiagnostic. Participants could have multiple concomitant index events. Regression was defined as (ie, unequivocal decrease \[\>50%\] of the total volume/mass of the thrombus compared to the index event)

Time frame:
From first dose (Day 1) up to 91 days
Reported as:
Count of participants · Participants
Number of Participants With Index Venous Thromboembolism (VTE) Status
ParticipantsParticipants Receiving ApixabanParticipants Treated With Standard of Care
Recurrence-contiguous20
Recurrence-new00
Unchanged86
Regression2511
Resolution7736
Indeterminate/Nondiagnostic157
Missing Follow-up Imaging, therefore cannot compare to baseline58
Imaging not completed within the specified time period61
SecondaryPercentage of Participants With Stroke

Participants were assessed for incidence of stroke.

Time frame:
From first dose (Day 1) up to 114 days
Reported as:
Number · percentage of participants
Percentage of Participants With Stroke
percentage of participantsParticipants Receiving ApixabanParticipants Treated With Standard of Care
Percentage of Participants With Stroke00
SecondaryPercentage of Participants With Symptomatic and Asymptomatic Recurrent Venous Thromboembolism (VTE)

Recurrent VTE, defined as either contiguous progression or non-contiguous new thrombus and including, but not limited to deep vein thrombosis (DVT), pulmonary embolism (PE) and paradoxical embolism. 95% CI was from the Agresti-Coull method.

Time frame:
From first dose (Day 1) up to 114 days
Reported as:
Number · percentage of participants
Percentage of Participants With Symptomatic and Asymptomatic Recurrent Venous Thromboembolism (VTE)
percentage of participantsParticipants Receiving ApixabanParticipants Treated With Standard of Care
Percentage of Participants With Symptomatic and Asymptomatic Recurrent Venous Thromboembolism (VTE)2.6 (0.8 to 6.7)2.7 (0.2 to 9.9)
SecondaryNumber of Participants With New Symptomatic or Asymptomatic Deep Vein Thrombosis (DVT) and New Symptomatic or Asymptomatic Pulmonary Embolism (PE)

Participants were assessed for incidence of Symptomatic or Asymptomatic Deep Vein Thrombosis (DVT) and New Symptomatic or Asymptomatic Pulmonary Embolism (PE).

Time frame:
From first dose (Day 1) up to 114 days
Reported as:
Count of participants · Participants
Number of Participants With New Symptomatic or Asymptomatic Deep Vein Thrombosis (DVT) and New Symptomatic or Asymptomatic Pulmonary Embolism (PE)
ParticipantsParticipants Receiving ApixabanParticipants Treated With Standard of Care
New Symptomatic or Asymptomatic DVT11
New Symptomatic or Asymptomatic PE00
SecondaryPercentage of Participants With Other Symptomatic and Asymptomatic Venous Thromboembolism (VTE)

Other VTE included events such as cerebral sinovenous thrombosis, renal vein thrombosis, portal vein thrombosis, catheter-related VTE, and splanchnic thrombosis. If VTE event type was blank, it was included in the Other VTE. 95% CI was from the Agresti-Coull method.

Time frame:
From first dose (Day 1) up to 114 days
Reported as:
Number · percentage of participants
Percentage of Participants With Other Symptomatic and Asymptomatic Venous Thromboembolism (VTE)
percentage of participantsParticipants Receiving ApixabanParticipants Treated With Standard of Care
Percentage of Participants With Other Symptomatic and Asymptomatic Venous Thromboembolism (VTE)1.9 (0.4 to 5.8)1.4 (0.0 to 8.0)
SecondaryNumber of Participants With Clinically Relevant Non-Major (CRNM) Bleeding, Major Bleeding and Minor Bleeding

Bleeding definitions are based on the Perinatal and Paediatric Haemostasis Subcommittee of the International Society on Thrombosis and Haemostasis (ISTH) criteria. Major bleeding includes: (i) fatal bleeding; (ii) clinically overt bleeding with a decrease in Hgb of at least 20 g/L (2 g/dL) in 24 hours; (iii) retroperitoneal, pulmonary, intracranial, or central nervous system bleeding; and (iv) bleeding requiring surgical intervention in an operating suite (including interventional radiology). Clinically relevant non-major bleeding includes: (i) overt bleeding requiring a blood product not attributable to the participant's underlying condition; and (ii) bleeding requiring medical or surgical intervention to restore hemostasis, other than in an operating suite. Minor bleeding was defined as any overt or macroscopic evidence of bleeding that does not fulfill the above criteria for either major bleeding or clinically relevant, non-major bleeding.

Time frame:
From first dose (Day 1) up to 114 days
Reported as:
Count of participants · Participants
Number of Participants With Clinically Relevant Non-Major (CRNM) Bleeding, Major Bleeding and Minor Bleeding
ParticipantsParticipants Receiving ApixabanParticipants Treated With Standard of Care
Major Bleeding00
Clinically Relevant Non-major Bleeding21
Minor Bleeding5421
SecondaryBlood Concentration of Apixaban (ng/mL)

Blood samples were collected to assess the apixaban concentration at specified timepoints. Day 1 PK concentrations were only collected for participants in the Birth to ≤27 days arm. The lower limit of quantification (LLOQ) is 1.0 ng/mL for plasma samples, and 0.5 ng/mL for dried blood samples.

Time frame:
3 hour (H), 12 H, 24 H at Day 3; pre and post dose at Day 14 and Day 42
Reported as:
Mean · nanogram per millilitre (ng/mL)
Blood Concentration of Apixaban (ng/mL)
nanogram per millilitre (ng/mL)Participants Between Age 12 to < 18 YearsParticipants Between Age 2 - < 12 YearsParticipants With Age 28 Days - < 2 YearsParticipants in Age Group-Birth - ≤ 27 Days
Hour 3 at Day 1———30.7 ± 12.9
Hour 12 at Day 1———13.9 ± 5.70
Hour 24 at Day 1———23.3 ± 10.1
Pre-dose at Day 1461.1 ± 53.772.7 ± 42.556.4 ± 65.648.3 ± 23.0
Post-dose at Day 14152 ± 80.2189 ± 61.0203 ± 118119 ± 45.7
Pre-dose at Day 4254.5 ± 33.767.9 ± 33.8123 ± 12350.2 ± 34.1
Post-Dose at Day 42151 ± 79.1212 ± 89.8143 ± 88.0109 ± 56.0
SecondaryConcentration of Plasma Anti-Factor Xa (ng/mL)

Blood samples were collected to assess the Anti-Factor Xa concentration at specified timepoints. Day 1 PK concentrations were only collected for participants in the Birth to ≤27 days arm. The lower limit of quantification (LLOQ) is 35.0 ng/mL.

Time frame:
Pre and post dose at Day 14 and Day 42
Reported as:
Mean · nanogram per millilitre (ng/mL)
Concentration of Plasma Anti-Factor Xa (ng/mL)
nanogram per millilitre (ng/mL)Participants Between Age 12 to < 18 YearsParticipants Between Age 2 - < 12 YearsParticipants With Age 28 Days - < 2 YearsParticipants in Age Group-Birth - ≤ 27 Days
Pre-dose at Day 1472.7 ± 60.482.7 ± 41.374.7 ± 69.748.0 ± 1.00
Post-dose at Day 14147 ± 83.5202 ± 75.8190 ± 105127 ± 4.04
Pre-dose at Day 4263.9 ± 27.475.3 ± 31.053.5 ± 13.4—
Post-Dose at Day 42153 ± 84.9220 ± 98.4156 ± 92.2101 ± NA

Adverse events

Collected over Non-Serious adverse events were collected from first dose Day 1 up to end of treatment visit (Day 168) plus 35 days i.e., up to 203 days. Serious Adverse Events and all cause mortality was collected from Screening (Day -7) to end of treatment visit (Day 168) plus 35 days i.e., up to 210 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Participants Receiving Apixaban2/155 (1.3%)40/152 (26.3%)132/152 (86.8%)
Participants Treated With Standard of Care1/74 (1.4%)17/73 (23.3%)59/73 (80.8%)
Most frequent serious events
Showing 10 of 90
Most frequent serious events
EventParticipants Receiving ApixabanParticipants Treated With Standard of Care
Febrile neutropeniaBlood and lymphatic system disorders3/1522/73
PyrexiaGeneral disorders4/1521/73
Alanine aminotransferase increasedInvestigations3/1520/73
Cardio-respiratory arrestCardiac disorders0/1521/73
Chest painGeneral disorders0/1521/73
Non-cardiac chest painGeneral disorders1/1521/73
Peripheral swellingGeneral disorders0/1521/73
Escherichia pyelonephritisInfections and infestations0/1521/73
PyomyositisInfections and infestations0/1521/73
VaricellaInfections and infestations0/1521/73
Most frequent other events
Showing 10 of 28
Most frequent other events
EventParticipants Receiving ApixabanParticipants Treated With Standard of Care
EpistaxisRespiratory, thoracic and mediastinal disorders27/15214/73
HeadacheNervous system disorders27/15210/73
Injection site bruisingGeneral disorders1/15212/73
VomitingGastrointestinal disorders22/1524/73
ContusionInjury, poisoning and procedural complications14/15210/73
AnaemiaBlood and lymphatic system disorders5/1528/73
Heavy menstrual bleedingReproductive system and breast disorders16/1523/73
DiarrhoeaGastrointestinal disorders15/1526/73
Pain in extremityMusculoskeletal and connective tissue disorders15/1526/73
PyrexiaGeneral disorders11/1527/73

Baseline characteristics

Age, Continuous
Age, Continuous(years)Participants Receiving ApixabanParticipants Treated With Standard of CareTotal
Mean11.10 ± 6.5111.68 ± 6.0211.29 ± 6.35
Sex: Female, Male
Sex: Female, Male(Participants)Participants Receiving ApixabanParticipants Treated With Standard of CareTotal
Female8543128
Male7031101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Participants Receiving ApixabanParticipants Treated With Standard of CareTotal
Hispanic or Latino121325
Not Hispanic or Latino14361204
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Participants Receiving ApixabanParticipants Treated With Standard of CareTotal
White12055175
Black22931
Asian549
American Indian or Alaska Native101
Other6511
Multiracial112
08

Study locations

128 sites
  • Pediatric Cardiology Clinic
    Birmingham, Alabama 35233, United States
  • University of Alabama
    Birmingham, Alabama 35233, United States
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • Loma Linda University Cancer Center
    Loma Linda, California 92350, United States
  • Loma Linda University Children's Hospital
    Loma Linda, California 92354, United States
  • Loma Linda University Medical Center
    Loma Linda, California 92354, United States
  • Valley Children's Hospital
    Madera, California 93636, United States
  • Children's Hospital and Research Center Oakland
    Oakland, California 94609, United States
  • Bass Speicalty Pharmacy
    Palo Alto, California 94304, United States
  • Inpatient Pharmacy
    Palo Alto, California 94304, United States
  • Lucile Packard Children's Hosptial - Stanford University
    Palo Alto, California 94304, United States
  • University of California Davis Comprehensive Cancer Center
    Sacramento, California 95817, United States
  • Loma Linda University Health Care
    San Bernardino, California 92408, United States
  • UCSF Benioff Children's Hospital
    San Francisco, California 94158, United States
  • UCSF Mission Bay Pediatric Clinical Research Center
    San Francisco, California 94158, United States
  • Children's Hospital Colorado - Investigational Drug Services
    Aurora, Colorado 80045, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Connecticut Children's Medical Center Pharmacy
    Hartford, Connecticut 06106, United States
  • Connecticut Children's Medical Center
    Hartford, Connecticut 06106, United States
  • Nemours/ Alfred I. duPont Hospital for Children
    Wilmington, Delaware 19803, United States
  • Childrens National Medical Center
    Washington, District of Columbia 20010, United States
  • UF Health Shands Hospital
    Gainesville, Florida 32610, United States
  • JDCH Division of Pediatric Hematology and Oncology
    Hollywood, Florida 33021, United States
  • Joe DiMaggio Children's Hospital
    Hollywood, Florida 33021, United States
  • Memorial Regional Hospital
    Hollywood, Florida 33021, United States
  • Nicklaus Children's Hospital
    Miami, Florida 33155, United States
  • AdventHealth Orlando
    Orlando, Florida 32803, United States
  • AdventHealth Orlando-Pharmacy Investigational Drug Services
    Orlando, Florida 32804, United States
  • AdventHealth Pediatric Oncology Hematology at Orlando
    Orlando, Florida 32804, United States
  • St. Joseph's Hospital
    Tampa, Florida 33607, United States
  • Children's Hematology and Oncology a division of Kidz medical Service
    West Palm Beach, Florida 33407, United States
  • St. Mary's Medical Center
    West Palm Beach, Florida 33407, United States
  • Children's Healthcare of Atlanta-Egleston
    Atlanta, Georgia 30322, United States
  • Children's Healthcare of Atlanta Center for Advanced Pediatrics - Pediatric Research Unit
    Atlanta, Georgia 30329, United States
  • Children's Healthcare of Atlanta Center for Advanced Pediatrics-IDS Pharmacy
    Atlanta, Georgia 30329, United States
  • Ann & Robert H Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Bleeding and Clotting Disorders Institute
    Peoria, Illinois 61614, United States
  • Unity Point Methodist Medical Center
    Peoria, Illinois 61636, United States
  • OSF Saint Francis Medical Center
    Peoria, Illinois 61637, United States
  • Indiana University
    Indianapolis, Indiana 46202-5225, United States
  • IU Health Pharmacy
    Indianapolis, Indiana 46202, United States
  • Riley Hospital for Children at IU Health
    Indianapolis, Indiana 46202, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • University of Kentucky Medical Center
    Lexington, Kentucky 40536, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Children's Hospital of Michigan
    Detroit, Michigan 48201, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • New York-Presbyterian Morgan Stanley Children's Hospital
    New York, New York 10032, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Levine Children's Specialty Center
    Charlotte, North Carolina 28203, United States
  • Levine Children's Hospital, Pediatric Research
    Charlotte, North Carolina 28207, United States
  • Levine Children's Hospital
    Charlotte, North Carolina 28207, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Investigational Drug Service, Duke University Hospital
    Durham, North Carolina 27710, United States
  • Sanford Children's Hospital
    Fargo, North Dakota 58104, United States
  • Sanford Roger Maris Cancer Center
    Fargo, North Dakota 58122, United States
  • Akron Children's Hospital
    Akron, Ohio 44308, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • OU Medical Center Investigational Drug Pharmacy
    Oklahoma City, Oklahoma 73104, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • St. Christopher's Hospital for Children
    Philadelphia, Pennsylvania 19134, United States
  • UPMC Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Medical University of South Carolina: Investigational Drug Services
    Charleston, South Carolina 29425, United States
  • Medical University of South Carolina: Shawn Jenkins Women's and Children's Hospital
    Charleston, South Carolina 29425, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232-7610, United States
  • Monroe Carell Jr. Children's Hospital at Vanderbilt
    Nashville, Tennessee 37232, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Texas Children's Hospital- Main Hospital
    Houston, Texas 77030, United States
  • Texas Children's Hospital- Wallace Tower
    Houston, Texas 77030, United States
  • The Children's Hospital of San Antonio
    San Antonio, Texas 78207, United States
  • University of Texas Health San Antonio
    San Antonio, Texas 78229, United States
  • Primary Children's Hospital
    Salt Lake City, Utah 84113, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Children's Hospital of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Versiti Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Kids Cancer Centre
    Randwick, New South Wales 2031, Australia
  • Prince of Wales Hospital
    Sydney, New South Wales 2031, Australia
  • The Royal Childrens Hospital
    Parkville, Victoria 3052, Australia
  • A.o.Landeskrankenhaus Innsbruck
    Innsbruck, Tyrol 6020, Austria
  • Medizinische Universitaet Innsbruck
    Innsbruck, 6020, Austria
  • Medizinische Universitaet Wien
    Wien, 1090, Austria
  • Kaye Edmonton Clinic
    Edmonton, Alberta T6G 1Z1, Canada
  • Stollery Children's Hospital
    Edmonton, Alberta T6G 2B7, Canada
  • Hamilton Health Science Corporation/McMaster Children's Hospital
    Hamilton, Ontario L8N3Z5, Canada
  • The Hospital For Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • CHU Sainte-Justine
    Montreal, Quebec H3T 1C5, Canada
  • Hopital de la Timone Enfants
    Marseille, 13385, France
  • CHRU de Montpellier - Hopital Arnaud de Villeneuve
    Montpellier Cedex 5, 34295, France
  • Hopital Necker-Enfants malades
    Paris, 75015, France
  • CHU de Bordeaux - Hopital Haut-Leveque
    PESSAC Cedex, 33604, France
  • Service d'Imagerie Medicale du Pr F. Laurent
    PESSAC Cedex, 33604, France

Showing the first 100 of 128 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Apr 2024, 101 months.

Results were first posted in Oct 2024, 5 months after primary completion.

Of 34 phase 4 interventional studies under Venous Thromboembolism, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 88. This study's 101 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2015
First posted
Jun 8, 2015
StartActual
Nov 22, 2015
Primary completionActual
Apr 30, 2024
CompletionActual
Apr 30, 2024
Results first posted
Oct 29, 2024
Last update
Oct 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02464969
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Jun 8, 2015
Start date
Nov 22, 2015
Primary completion
Apr 30, 2024
Completion
Apr 30, 2024
Results posted
Oct 29, 2024
Last update
Oct 29, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion